Japan’s regulator approves Grifols’ Lynspad

Japan’s regulator approves Grifols’ Lynspad™ [alpha-1 proteinase inhibitor] for the treatment of alpha-1 antitrypsin deficiency

Barcelona, Spain, and Tokyo, January 22, 2021 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines with a more than 100-year track record of contributing to the health and well-being of people around the world, and OrphanPacific, Inc., which provides drugs for rare diseases and disorders in Japan, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted manufacturing and marketing approval for Lynspad™ (intravenous infusion 1000 mg), an alpha-1 proteinase inhibitor to treat severe alpha-1 antitrypsin deficiency (AATD) in Japan.

Please visit OrphanPacific’s website for more details of the press release :
English Press Release: Japan’s regulator approves Grifols’ Lynspad™ [alpha-1 proteinase inhibitor] for the treatment of alpha-1 antitrypsin deficiency

Inquiries about our services

Click below if you are interested in outsourcing your operations to us.

For access to this link, please complete this short form.
Name*
First Last
Company Name*
Email*
Country*
State*
How did you hear about us?*
Mailing
- Sign me up for future communications from CMIC Group
Name
This field is for validation purposes and should be left unchanged.

EN | JP

Inquiries about our services

For access to this link, please complete this short form.